2026-04-17T14:19:17Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/119782025-10-24T10:28:41Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Esteban, Paula
author
Rota, Rosa
author
Álvarez-Navascúes, Carmen
author
Perez Medrano, Indhira
author
Riveiro-Barciela, Mar
author
Barreira, Ana
author
Ruiz Cobo, Juan Carlos
2025-10-24T10:28:41Z
2025-10-24T10:28:41Z
2024-09-27T12:06:10Z2024-09-27T12:06:10Z2024-09
http://hdl.handle.net/11351/11978
Anti‐CD20 monoclonal antibodies; Autoimmune hepatitis; CorticosteroidsAnticuerpos monoclonales anti‐CD20; Hepatitis autoinmune; CorticosteroidesAnticossos monoclonals anti-CD20; Hepatitis autoimmune; CorticoidesBackground and Aims
Small series suggest that rituximab could be effective as treatment for autoimmune hepatitis (AIH), although data are scarce. We aimed to evaluate the efficacy and safety of rituximab in different cohorts of patients with AIH.
Methods
Multicentre retrospective analysis of the 35 patients with AIH and its variant forms treated with rituximab and included in the ColHai registry between 2015 and 2023.
Results
Most patients were female (83%), 10 (29%) had cirrhosis and four (11.4%) variant forms of AIH. Indication for rituximab were as follows: 14(40%) refractory AIH, 19(54%) concomitant autoimmune or haematological disorder, 2(6%) intolerance to prior treatments. In three (9%) subjects with a concomitant disorder, rituximab was the first therapy for AIH. Overall, 31 (89%) patients achieved or maintained complete biochemical response (CBR), including the three in first-line therapy. No difference in CBR was observed according to rituximab indication (refractory AIH 86% vs. concomitant disorders 90%, p = .824) or cirrhosis (80% vs. 92%, p = .319). Rituximab was associated with a significant reduction in corticosteroids (median dose: prior 20 vs. post 5 mg, p < .001) and the discontinuation of ≥1 immunosuppressant in 47% of patients. Flare-free rate at 1st, 2nd and 3rd year was 86%, 73% and 62% respectively. Flares were not associated with the development of liver failure and were successfully managed with repeated doses of rituximab and/or increased corticosteroids. Three (9%) patients experienced infusion-related adverse events (1 anaphylaxis and 2 flu-like symptoms) and five (14%) infections.
Conclusion
Rituximab is safe and effective in patients with refractory AIH and those treated due to concomitant autoimmune or haematological disorders.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Avaluació de resultats (Assistència sanitària)
Hepatitis - Tractament
Anticossos monoclonals - Ús terapèutic
Hepatitis - Aspectes immunològics
DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Hepatitis, Autoimmune
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
Other subheadings::Other subheadings::/therapeutic use
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::hepatitis autoinmune
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales
Otros calificadores::Otros calificadores::/uso terapéutico
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion